Pregled bibliografske jedinice broj: 1000382
The association of semaphorins 3C, 5A and 6D with liver fibrosis stage in chronic hepatitis C
The association of semaphorins 3C, 5A and 6D with liver fibrosis stage in chronic hepatitis C // PLoS One, 13 (2018), 12; e0209481, 12 doi:10.1371/journal.pone.0209481 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1000382 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The association of semaphorins 3C, 5A and 6D with liver
fibrosis stage in chronic hepatitis C
Autori
Papić, Neven ; Židovec Lepej, Snježana ; Gorenec, Lana ; Grgić, Ivana ; Gašparov, Slavko ; Filipec Kanižaj, Tajana ; Vince, Adriana
Izvornik
PLoS One (1932-6203) 13
(2018), 12;
E0209481, 12
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
semaphorins 3C, 5A and 6D, liver fibrosis, chronic hepatitis C
Sažetak
Semaphorins are a diverse family of immunoregulators recently recognized to play a major role in various phases of immune responses. Their role in chronic viral hepatitis C (CHC) and contribution to the progression of liver disease is unknown. The aim of this study was to analyse the association of secreted semaphorins with the severity of liver disease in patients with CHC. Serum concentrations of semaphorins were measured in 114 treatment-naive CHC patients and 36 healthy controls. Serum concentrations of SEMA3A, SEMA3C, SEMA5A, SEMA6B and SEMA6D were significantly increased in patients with CHC compared to controls. While serum concentrations of SEMA3C and SEMA6D significantly increased with fibrosis stage in both HCV-g1 and HCV-g3 infections, the concentration of SEMA5A inversely correlated with fibrosis stage in both HCV genotypes. ROC analysis showed that serum concentrations of SEMA3C (>4.0ng/mL, AUC 0.88) and SEMA6D (>4.5, AUC 0.82) had higher AUC than widely used APRI (AUC 0.71) and FIB-4 (AUC 0.74) scores. Serum concentrations of SEMA3C and SEMA6D significantly decreased after DAA and PEG IFN- α/ribavirin therapy, while the serum concentration of SEMA5A significantly increased after DAAs therapy. Immunohistochemistry confirmed the expression of SEMA3C and SEMA5A in hepatocytes, endothelial cells and lymphocytes of cirrhotic livers from CHC patients but not in controls. In conclusion, we provide the first evidence that SEMA3C, SEMA5A and SEMA6D can be considered as markers of liver injury in CHC.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
MZOS-143-0000000-0117 - Imunopatogeneza hepatitisa B i C (Vince, Adriana, MZOS ) ( CroRIS)
MZOS-143-1080116-0097 - Imunološka rekonstitucija i rezistencija na lijekove u HIV-bolesnika iz Hrvatske (Židovec-Lepej, Snježana, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Klinika za infektivne bolesti "Dr Fran Mihaljević"
Profili:
Tajana Filipec Kanižaj
(autor)
Ivana Grgić
(autor)
Neven Papić
(autor)
Lana Gorenec
(autor)
Snježana Židovec-Lepej
(autor)
Adriana Vince
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE